By targeting the intestine, PAS-LAR can cause or exacerbate diabetes mellitus by strongly inhibiting GLP-1 or GIP secretion
Newman NJ, Bruce BB, Biousse V (2025) GLP-1 RAs for idiopathic intracranial hypertensiontime for a trial
Clinical trials showed that 9 out of 10 patients experienced improvement within 4 weeks, with 69% achieving at least a clinically significant reduction in symptoms
Register to access a library of procedural videos, case studies, training resources, and events
There is never any down time with these injections
SKIN BARRIER: Fast absorption into the skin to provide relief for dry, itchy skin and strengthens the skin barrier for healthy glowing skin